Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection
This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy...
Saved in:
| Published in | Vaccine Vol. 32; no. 51; pp. 7005 - 7013 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ltd
05.12.2014
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 1873-2518 |
| DOI | 10.1016/j.vaccine.2014.09.072 |
Cover
Loading…
| Abstract | This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-treated HIV-1-infected individuals, with the objective to reverse residual T-cell dysfunction.
Twelve HIV-1+ patients on suppressive cART with baseline CD4 T-cell counts >400cells/mm3 blood were randomised into one of three groups: (1) vaccine, IL-2, GM-CSF and rhGH (n=3); (2) vaccine alone (n=4); or (3) IL-2, GM-CSF and rhGH (n=5). Samples were collected at weeks 0, 1, 2, 4, 6, 8, 12, 16, 24 and 48. Interferon (IFN)-γ, IL-2, IL-4 and perforin ELISpot assays performed at each time point quantified functional responses to Gag p17/p24, Nef, Rev, and Tat peptides; and detailed T-cell immunophenotyping was undertaken by flow cytometry. Proviral DNA was also measured.
Median baseline CD4 T-cell count was 757cells/mm3 (interquartile range [IQR] 567–886cells/mm3), median age 48 years (IQR 42–51 years), and plasma HIV-1-RNA <50copies/ml for all subjects. Patients who received vaccine plus IL-2, GM-CSF and rhGH (group 1) showed the most marked changes. Assessing mean changes from baseline to week 48 revealed significantly elevated numbers of CD4 T cells (p=0.0083) and improved CD4/CD8 T-cell ratios (p=0.0033). This was accompanied by a significant reduction in expression of CD38 on CD4 T cells (p=0.0194), significantly increased IFN-γ and IL-2 production in response to Gag (p=0.0122) and elevated IFN-γ production in response to Tat (p=0.041) at week 48 compared to baseline. Subjects in all treatment groups showed significantly reduced PD-1 expression at week 48 compared to baseline, with some reductions in proviral DNA.
Multifarious immunotherapeutic approaches in the context of fully suppressive cART further reduce immune activation, and improve both CD4 T-lymphocyte counts and HIV-1-specific T-cell responses (NCT01130376). |
|---|---|
| AbstractList | This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-treated HIV-1-infected individuals, with the objective to reverse residual T-cell dysfunction.
Twelve HIV-1+ patients on suppressive cART with baseline CD4 T-cell counts >400cells/mm3 blood were randomised into one of three groups: (1) vaccine, IL-2, GM-CSF and rhGH (n=3); (2) vaccine alone (n=4); or (3) IL-2, GM-CSF and rhGH (n=5). Samples were collected at weeks 0, 1, 2, 4, 6, 8, 12, 16, 24 and 48. Interferon (IFN)-γ, IL-2, IL-4 and perforin ELISpot assays performed at each time point quantified functional responses to Gag p17/p24, Nef, Rev, and Tat peptides; and detailed T-cell immunophenotyping was undertaken by flow cytometry. Proviral DNA was also measured.
Median baseline CD4 T-cell count was 757cells/mm3 (interquartile range [IQR] 567–886cells/mm3), median age 48 years (IQR 42–51 years), and plasma HIV-1-RNA <50copies/ml for all subjects. Patients who received vaccine plus IL-2, GM-CSF and rhGH (group 1) showed the most marked changes. Assessing mean changes from baseline to week 48 revealed significantly elevated numbers of CD4 T cells (p=0.0083) and improved CD4/CD8 T-cell ratios (p=0.0033). This was accompanied by a significant reduction in expression of CD38 on CD4 T cells (p=0.0194), significantly increased IFN-γ and IL-2 production in response to Gag (p=0.0122) and elevated IFN-γ production in response to Tat (p=0.041) at week 48 compared to baseline. Subjects in all treatment groups showed significantly reduced PD-1 expression at week 48 compared to baseline, with some reductions in proviral DNA.
Multifarious immunotherapeutic approaches in the context of fully suppressive cART further reduce immune activation, and improve both CD4 T-lymphocyte counts and HIV-1-specific T-cell responses (NCT01130376). This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-treated HIV-1-infected individuals, with the objective to reverse residual T-cell dysfunction.Twelve HIV-1+ patients on suppressive cART with baseline CD4 T-cell counts >400cells/mm3 blood were randomised into one of three groups: (1) vaccine, IL-2, GM-CSF and rhGH (n=3); (2) vaccine alone (n=4); or (3) IL-2, GM-CSF and rhGH (n=5). Samples were collected at weeks 0, 1, 2, 4, 6, 8, 12, 16, 24 and 48. Interferon (IFN)-γ, IL-2, IL-4 and perforin ELISpot assays performed at each time point quantified functional responses to Gag p17/p24, Nef, Rev, and Tat peptides; and detailed T-cell immunophenotyping was undertaken by flow cytometry. Proviral DNA was also measured.Median baseline CD4 T-cell count was 757cells/mm3 (interquartile range [IQR] 567–886cells/mm3), median age 48 years (IQR 42–51 years), and plasma HIV-1-RNA <50copies/ml for all subjects. Patients who received vaccine plus IL-2, GM-CSF and rhGH (group 1) showed the most marked changes. Assessing mean changes from baseline to week 48 revealed significantly elevated numbers of CD4 T cells (p=0.0083) and improved CD4/CD8 T-cell ratios (p=0.0033). This was accompanied by a significant reduction in expression of CD38 on CD4 T cells (p=0.0194), significantly increased IFN-γ and IL-2 production in response to Gag (p=0.0122) and elevated IFN-γ production in response to Tat (p=0.041) at week 48 compared to baseline. Subjects in all treatment groups showed significantly reduced PD-1 expression at week 48 compared to baseline, with some reductions in proviral DNA.Multifarious immunotherapeutic approaches in the context of fully suppressive cART further reduce immune activation, and improve both CD4 T-lymphocyte counts and HIV-1-specific T-cell responses (NCT01130376). Background This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-treated HIV-1-infected individuals, with the objective to reverse residual T-cell dysfunction. Methods Twelve HIV-1+patients on suppressive cART with baseline CD4 T-cell counts >400cells/mm3blood were randomised into one of three groups: (1) vaccine, IL-2, GM-CSF and rhGH (n=3); (2) vaccine alone (n=4); or (3) IL-2, GM-CSF and rhGH (n=5). Samples were collected at weeks 0, 1, 2, 4, 6, 8, 12, 16, 24 and 48. Interferon (IFN)-γ, IL-2, IL-4 and perforin ELISpot assays performed at each time point quantified functional responses to Gag p17/p24, Nef, Rev, and Tat peptides; and detailed T-cell immunophenotyping was undertaken by flow cytometry. Proviral DNA was also measured. Results Median baseline CD4 T-cell count was 757cells/mm3(interquartile range 567-886cells/mm3), median age 48 years (IQR 42-51 years), and plasma HIV-1-RNA <50copies/ml for all subjects. Patients who received vaccine plus IL-2, GM-CSF and rhGH (group 1) showed the most marked changes. Assessing mean changes from baseline to week 48 revealed significantly elevated numbers of CD4 T cells (p=0.0083) and improved CD4/CD8 T-cell ratios (p=0.0033). This was accompanied by a significant reduction in expression of CD38 on CD4 T cells (p=0.0194), significantly increased IFN-γ and IL-2 production in response to Gag (p=0.0122) and elevated IFN-γ production in response to Tat (p=0.041) at week 48 compared to baseline. Subjects in all treatment groups showed significantly reduced PD-1 expression at week 48 compared to baseline, with some reductions in proviral DNA. Conclusions Multifarious immunotherapeutic approaches in the context of fully suppressive cART further reduce immune activation, and improve both CD4 T-lymphocyte counts and HIV-1-specific T-cell responses (NCT01130376). Background This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-treated HIV-1-infected individuals, with the objective to reverse residual T-cell dysfunction. Methods Twelve HIV-1+ patients on suppressive cART with baseline CD4 T-cell counts >400cells/mm3 blood were randomised into one of three groups: (1) vaccine, IL-2, GM-CSF and rhGH (n=3); (2) vaccine alone (n=4); or (3) IL-2, GM-CSF and rhGH (n=5). Samples were collected at weeks 0, 1, 2, 4, 6, 8, 12, 16, 24 and 48. Interferon (IFN)- gamma , IL-2, IL-4 and perforin ELISpot assays performed at each time point quantified functional responses to Gag p17/p24, Nef, Rev, and Tat peptides; and detailed T-cell immunophenotyping was undertaken by flow cytometry. Proviral DNA was also measured. Results Median baseline CD4 T-cell count was 757cells/mm3 (interquartile range [IQR] 567-886cells/mm3), median age 48 years (IQR 42-51 years), and plasma HIV-1-RNA <50copies/ml for all subjects. Patients who received vaccine plus IL-2, GM-CSF and rhGH (group 1) showed the most marked changes. Assessing mean changes from baseline to week 48 revealed significantly elevated numbers of CD4 T cells (p=0.0083) and improved CD4/CD8 T-cell ratios (p=0.0033). This was accompanied by a significant reduction in expression of CD38 on CD4 T cells (p=0.0194), significantly increased IFN- gamma and IL-2 production in response to Gag (p=0.0122) and elevated IFN- gamma production in response to Tat (p=0.041) at week 48 compared to baseline. Subjects in all treatment groups showed significantly reduced PD-1 expression at week 48 compared to baseline, with some reductions in proviral DNA. Conclusions Multifarious immunotherapeutic approaches in the context of fully suppressive cART further reduce immune activation, and improve both CD4 T-lymphocyte counts and HIV-1-specific T-cell responses (NCT01130376). Abstract Background This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-treated HIV-1-infected individuals, with the objective to reverse residual T-cell dysfunction. Methods Twelve HIV-1+ patients on suppressive cART with baseline CD4 T-cell counts >400 cells/mm3 blood were randomised into one of three groups: (1) vaccine, IL-2, GM-CSF and rhGH ( n = 3); (2) vaccine alone ( n = 4); or (3) IL-2, GM-CSF and rhGH ( n = 5). Samples were collected at weeks 0, 1, 2, 4, 6, 8, 12, 16, 24 and 48. Interferon (IFN)-γ, IL-2, IL-4 and perforin ELISpot assays performed at each time point quantified functional responses to Gag p17/p24, Nef, Rev, and Tat peptides; and detailed T-cell immunophenotyping was undertaken by flow cytometry. Proviral DNA was also measured. Results Median baseline CD4 T-cell count was 757 cells/mm3 (interquartile range [IQR] 567–886 cells/mm3 ), median age 48 years (IQR 42–51 years), and plasma HIV-1-RNA <50 copies/ml for all subjects. Patients who received vaccine plus IL-2, GM-CSF and rhGH (group 1) showed the most marked changes. Assessing mean changes from baseline to week 48 revealed significantly elevated numbers of CD4 T cells ( p = 0.0083) and improved CD4/CD8 T-cell ratios ( p = 0.0033). This was accompanied by a significant reduction in expression of CD38 on CD4 T cells ( p = 0.0194), significantly increased IFN-γ and IL-2 production in response to Gag ( p = 0.0122) and elevated IFN-γ production in response to Tat ( p = 0.041) at week 48 compared to baseline. Subjects in all treatment groups showed significantly reduced PD-1 expression at week 48 compared to baseline, with some reductions in proviral DNA. Conclusions Multifarious immunotherapeutic approaches in the context of fully suppressive cART further reduce immune activation, and improve both CD4 T-lymphocyte counts and HIV-1-specific T-cell responses ( NCT01130376 ). This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-treated HIV-1-infected individuals, with the objective to reverse residual T-cell dysfunction. Twelve HIV-1(+) patients on suppressive cART with baseline CD4 T-cell counts >400 cells/mm(3) blood were randomised into one of three groups: (1) vaccine, IL-2, GM-CSF and rhGH (n=3); (2) vaccine alone (n=4); or (3) IL-2, GM-CSF and rhGH (n=5). Samples were collected at weeks 0, 1, 2, 4, 6, 8, 12, 16, 24 and 48. Interferon (IFN)-γ, IL-2, IL-4 and perforin ELISpot assays performed at each time point quantified functional responses to Gag p17/p24, Nef, Rev, and Tat peptides; and detailed T-cell immunophenotyping was undertaken by flow cytometry. Proviral DNA was also measured. Median baseline CD4 T-cell count was 757 cells/mm(3) (interquartile range [IQR] 567-886 cells/mm(3)), median age 48 years (IQR 42-51 years), and plasma HIV-1-RNA <50 copies/ml for all subjects. Patients who received vaccine plus IL-2, GM-CSF and rhGH (group 1) showed the most marked changes. Assessing mean changes from baseline to week 48 revealed significantly elevated numbers of CD4 T cells (p=0.0083) and improved CD4/CD8 T-cell ratios (p=0.0033). This was accompanied by a significant reduction in expression of CD38 on CD4 T cells (p=0.0194), significantly increased IFN-γ and IL-2 production in response to Gag (p=0.0122) and elevated IFN-γ production in response to Tat (p=0.041) at week 48 compared to baseline. Subjects in all treatment groups showed significantly reduced PD-1 expression at week 48 compared to baseline, with some reductions in proviral DNA. Multifarious immunotherapeutic approaches in the context of fully suppressive cART further reduce immune activation, and improve both CD4 T-lymphocyte counts and HIV-1-specific T-cell responses (NCT01130376). This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-treated HIV-1-infected individuals, with the objective to reverse residual T-cell dysfunction.BACKGROUNDThis randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-treated HIV-1-infected individuals, with the objective to reverse residual T-cell dysfunction.Twelve HIV-1(+) patients on suppressive cART with baseline CD4 T-cell counts >400 cells/mm(3) blood were randomised into one of three groups: (1) vaccine, IL-2, GM-CSF and rhGH (n=3); (2) vaccine alone (n=4); or (3) IL-2, GM-CSF and rhGH (n=5). Samples were collected at weeks 0, 1, 2, 4, 6, 8, 12, 16, 24 and 48. Interferon (IFN)-γ, IL-2, IL-4 and perforin ELISpot assays performed at each time point quantified functional responses to Gag p17/p24, Nef, Rev, and Tat peptides; and detailed T-cell immunophenotyping was undertaken by flow cytometry. Proviral DNA was also measured.METHODSTwelve HIV-1(+) patients on suppressive cART with baseline CD4 T-cell counts >400 cells/mm(3) blood were randomised into one of three groups: (1) vaccine, IL-2, GM-CSF and rhGH (n=3); (2) vaccine alone (n=4); or (3) IL-2, GM-CSF and rhGH (n=5). Samples were collected at weeks 0, 1, 2, 4, 6, 8, 12, 16, 24 and 48. Interferon (IFN)-γ, IL-2, IL-4 and perforin ELISpot assays performed at each time point quantified functional responses to Gag p17/p24, Nef, Rev, and Tat peptides; and detailed T-cell immunophenotyping was undertaken by flow cytometry. Proviral DNA was also measured.Median baseline CD4 T-cell count was 757 cells/mm(3) (interquartile range [IQR] 567-886 cells/mm(3)), median age 48 years (IQR 42-51 years), and plasma HIV-1-RNA <50 copies/ml for all subjects. Patients who received vaccine plus IL-2, GM-CSF and rhGH (group 1) showed the most marked changes. Assessing mean changes from baseline to week 48 revealed significantly elevated numbers of CD4 T cells (p=0.0083) and improved CD4/CD8 T-cell ratios (p=0.0033). This was accompanied by a significant reduction in expression of CD38 on CD4 T cells (p=0.0194), significantly increased IFN-γ and IL-2 production in response to Gag (p=0.0122) and elevated IFN-γ production in response to Tat (p=0.041) at week 48 compared to baseline. Subjects in all treatment groups showed significantly reduced PD-1 expression at week 48 compared to baseline, with some reductions in proviral DNA.RESULTSMedian baseline CD4 T-cell count was 757 cells/mm(3) (interquartile range [IQR] 567-886 cells/mm(3)), median age 48 years (IQR 42-51 years), and plasma HIV-1-RNA <50 copies/ml for all subjects. Patients who received vaccine plus IL-2, GM-CSF and rhGH (group 1) showed the most marked changes. Assessing mean changes from baseline to week 48 revealed significantly elevated numbers of CD4 T cells (p=0.0083) and improved CD4/CD8 T-cell ratios (p=0.0033). This was accompanied by a significant reduction in expression of CD38 on CD4 T cells (p=0.0194), significantly increased IFN-γ and IL-2 production in response to Gag (p=0.0122) and elevated IFN-γ production in response to Tat (p=0.041) at week 48 compared to baseline. Subjects in all treatment groups showed significantly reduced PD-1 expression at week 48 compared to baseline, with some reductions in proviral DNA.Multifarious immunotherapeutic approaches in the context of fully suppressive cART further reduce immune activation, and improve both CD4 T-lymphocyte counts and HIV-1-specific T-cell responses (NCT01130376).CONCLUSIONSMultifarious immunotherapeutic approaches in the context of fully suppressive cART further reduce immune activation, and improve both CD4 T-lymphocyte counts and HIV-1-specific T-cell responses (NCT01130376). |
| Author | Stanescu, Ioana Imami, Nesrina Moyle, Graeme Downey, Jocelyn Mandalia, Sundhiya Herasimtschuk, Anna Sikut, Rein Gotch, Frances Nelson, Mark Adojaan, Maarja |
| Author_xml | – sequence: 1 givenname: Anna surname: Herasimtschuk fullname: Herasimtschuk, Anna organization: Imperial College London, London, UK – sequence: 2 givenname: Jocelyn surname: Downey fullname: Downey, Jocelyn organization: Imperial College London, London, UK – sequence: 3 givenname: Mark surname: Nelson fullname: Nelson, Mark organization: Chelsea and Westminster Hospital, London, UK – sequence: 4 givenname: Graeme surname: Moyle fullname: Moyle, Graeme organization: Chelsea and Westminster Hospital, London, UK – sequence: 5 givenname: Sundhiya surname: Mandalia fullname: Mandalia, Sundhiya organization: Imperial College London, London, UK – sequence: 6 givenname: Rein surname: Sikut fullname: Sikut, Rein organization: FIT Biotech Ltd., Tartu, Estonia – sequence: 7 givenname: Maarja surname: Adojaan fullname: Adojaan, Maarja organization: FIT Biotech Ltd., Tartu, Estonia – sequence: 8 givenname: Ioana surname: Stanescu fullname: Stanescu, Ioana organization: FIT Biotech Ltd., Tampere, Finland – sequence: 9 givenname: Frances surname: Gotch fullname: Gotch, Frances organization: Imperial College London, London, UK – sequence: 10 givenname: Nesrina surname: Imami fullname: Imami, Nesrina email: n.imami@imperial.ac.uk organization: Imperial College London, London, UK |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=29054372$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/25454870$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkl2LEzEUhoOsuLvVn6AERPDCqfmeCaIg9WMXFrywyt6FNJOh6U6TmmQK_WH-PzNtl4UF6U0yE573vOdw3ktw5oO3ALzEaIoRFu9X0602xnk7JQizKZJTVJMn4AI3Na0Ix80ZuEBEsIphdHsOLlNaIYQ4xfIZOCeccdbU6AL8nS9t1Bs7ZGegW68H75LOLni46YcEzS6Hu2ICtW_hMsR1aQLmvWRX8E0MW5vg7AuD88rYvocmDD6ndzDalEM5ijC76ur6d4XHt03waf_Ylr92MOV7b1oMTHbbg7PzMEers22hWcbgS2eHAs531ozIc_C0032yL473BPz69nU-u6pufny_nn2-qQxnJFeLRthOEMRb2lFBzcLwDnHDjMaW1xQb2ehac9pyZiSjAjFhZdcupCZISFTTCXh7qFsG_TOUkdTapXFO7W0YksINExRzIZvTqOCEUSrKcRqlHJUOyj0Brx-hqzBEX2YuFOENJUTKQr06UsNibVu1iW6t407dr7kAb46ATkb3XdTeuPTAScQZrUnhPhw4E0NK0XbKuLxfSo7a9QojNYZPrdQxfGoMn0JSob2aP1LfG5zSfTrobFnl1tmoTO_K1nV_Z3c2PUysElFI_RxjPaYaM4Rpw25LgY__L6Da4E408A-fAAtS |
| CODEN | VACCDE |
| CitedBy_id | crossref_primary_10_1016_j_clicom_2023_02_005 crossref_primary_10_3389_fimmu_2021_632119 crossref_primary_10_1038_s41598_020_66964_0 crossref_primary_10_1007_s12064_016_0234_x crossref_primary_10_18632_oncotarget_7793 crossref_primary_10_1186_s12977_016_0261_1 crossref_primary_10_1038_srep36234 crossref_primary_10_1002_oca_2555 crossref_primary_10_1016_j_psj_2024_104514 crossref_primary_10_1089_aid_2018_0176 crossref_primary_10_3389_fmicb_2022_900041 crossref_primary_10_7448_IAS_18_1_20497 crossref_primary_10_1080_21645515_2015_1021523 crossref_primary_10_1097_QAI_0000000000000734 crossref_primary_10_26685_urncst_128 |
| Cites_doi | 10.1371/journal.pone.0019252 10.1186/1476-8518-3-7 10.1089/aid.2009.0052 10.1111/j.1365-2249.2005.02918.x 10.1056/NEJMoa062360 10.1186/1476-8518-5-6 10.1097/00126334-200407010-00004 10.1056/NEJMoa0903175 10.1086/346056 10.1097/00002030-200411050-00014 10.1016/j.vaccine.2009.10.054 10.1016/j.micinf.2005.07.023 10.1016/S0140-6736(06)69162-9 10.1634/theoncologist.12-S2-22 10.1111/cei.12141 10.1006/clim.2001.5164 10.1016/j.vaccine.2007.05.040 10.1126/science.1165706 10.4049/jimmunol.1000156 10.1186/1476-8518-3-3 10.1097/QAD.0b013e3283303307 10.1097/QAI.0b013e3181fbab9f 10.1046/j.1365-2249.1999.01012.x 10.1097/00002030-200303070-00020 10.1111/imr.12083 10.1016/j.jim.2005.11.005 10.1097/00002030-200205240-00003 10.2217/17469600.1.2.171 10.1097/00002030-200305230-00002 10.1016/j.vaccine.2012.04.007 10.1182/blood.V88.1.202.202 10.1111/j.1600-065X.1999.tb01337.x 10.1186/1476-8518-6-7 10.1016/j.vaccine.2011.01.064 10.1371/journal.pone.0018164 10.1097/QAD.0b013e32833b61ba 10.1128/CVI.05045-11 10.1097/00126334-200404010-00006 10.1517/14712598.1.5.803 10.1038/nature08898 10.4049/jimmunol.174.4.1913 10.1097/00002030-200302140-00008 10.1172/JCI67008 10.1038/nm866 10.1177/135965350400900110 10.1089/aid.2006.22.667 10.3389/fimmu.2013.00058 10.1111/j.1365-2249.2011.04451.x |
| ContentType | Journal Article |
| Copyright | 2014 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright © 2014 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Dec 5, 2014 |
| Copyright_xml | – notice: 2014 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2014 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Dec 5, 2014 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2014.09.072 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Database ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database ProQuest Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Biological Science Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA Research Library Prep AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 7013 |
| ExternalDocumentID | 3500056981 25454870 29054372 10_1016_j_vaccine_2014_09_072 1_s2_0_S0264410X1401384X S0264410X1401384X |
| Genre | Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Medical Research Council grantid: G0501957 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ABWVN ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP AIGII APXCP CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c542t-b86ef6205d3f363cbc5f05c4ca1e5731c98a7a53d54c9436046e9fdb9a2069073 |
| IEDL.DBID | 7X7 |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Tue Aug 05 11:06:19 EDT 2025 Tue Aug 05 10:02:35 EDT 2025 Fri Jul 11 14:50:51 EDT 2025 Wed Aug 13 08:44:23 EDT 2025 Thu Apr 03 07:00:44 EDT 2025 Wed Apr 02 07:26:57 EDT 2025 Tue Jul 01 03:38:11 EDT 2025 Thu Apr 24 22:57:34 EDT 2025 Sun Feb 23 10:19:19 EST 2025 Tue Aug 26 16:33:24 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 51 |
| Keywords | HIV-1 DNA vaccine Immune-based therapy Hormone Immunopathology Immunization CD4 T lymphocyte Immune response HIV-1 virus Cytokine Retroviridae AIDS Genetic vaccine Immune deficiency Lentivirus Infection Virus Chronic Treatment Viral disease Human immunodeficiency virus |
| Language | English |
| License | CC BY 4.0 Copyright © 2014 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c542t-b86ef6205d3f363cbc5f05c4ca1e5731c98a7a53d54c9436046e9fdb9a2069073 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 25454870 |
| PQID | 1625832299 |
| PQPubID | 105530 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1846315698 proquest_miscellaneous_1652433624 proquest_miscellaneous_1635020616 proquest_journals_1625832299 pubmed_primary_25454870 pascalfrancis_primary_29054372 crossref_citationtrail_10_1016_j_vaccine_2014_09_072 crossref_primary_10_1016_j_vaccine_2014_09_072 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X1401384X elsevier_clinicalkey_doi_10_1016_j_vaccine_2014_09_072 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-12-05 |
| PublicationDateYYYYMMDD | 2014-12-05 |
| PublicationDate_xml | – month: 12 year: 2014 text: 2014-12-05 day: 05 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: Netherlands |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2014 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Herasimtschuk, Westrop, Moyle, Downey, Imami (bib0140) 2008; 6 Gudmundsdotter, Wahren, Haller, Boberg, Edback, Bernasconi (bib0210) 2011; 29 Virgin, Walker (bib0240) 2010; 464 Burton, Gotch, Imami (bib0170) 2006; 308 Krohn, Stanescu, Blazevic, Vesikari, Ranki, Ustav (bib0155) 2005; 7 Hocqueloux, Prazuck, Avettand-Fenoel, Lafeuillade, Cardon, Viard (bib0035) 2010; 24 Blattman, Grayson, Wherry, Kaech, Smith, Ahmed (bib0065) 2003; 9 Hardy, Imami, Nelson, Sullivan, Moss, Aasa-Chapman (bib0205) 2007; 5 Blazevic, Mannik, Malm, Sikut, Valtavaara, Toots (bib0160) 2006; 22 Molder, Adojaan, Kaldma, Ustav, Sikut (bib0165) 2009; 28 Cellerai, Harari, Stauss, Yerly, Geretti, Carroll (bib0225) 2011; 6 Imami, Westrop, Cranage, Burton, Gotch (bib0015) 2007; 1 Vardas, Stanescu, Leinonen, Ellefsen, Pantaleo, Valtavaara (bib0055) 2012; 30 Nacsa, Edghill-Smith, Tsai, Venzon, Tryniszewska, Hryniewicz (bib0070) 2005; 174 Imami, Westrop, Grageda, Herasimtschuk (bib0045) 2013; 4 Valdez, Mitsuyasu, Landay, Sevin, Chan, Spritzler (bib0080) 2003; 187 Pires, Hardy, Gazzard, Gotch, Imami (bib0010) 2004; 36 Imami, Hardy, Gotch (bib0040) 2001; 1 Toubaji, Hill, Terabe, Qian, Floyd, Simpson (bib0105) 2007; 25 Waller (bib0100) 2007; 12 Adojaan, Kivisild, Mannik, Krispin, Ustina, Zilmer (bib0175) 2005; 39 El-Sadr, Lundgren, Neaton, Gordin, Abrams, Arduino (bib0030) 2006; 355 Richman, Margolis, Delaney, Greene, Hazuda, Pomerantz (bib0020) 2009; 323 Smith, Zheng, Bosch, Margolis, Tenorio, Napolitano (bib0130) 2010; 26 Hardy, Imami, Sullivan, Nelson, Gazzard, Gotch (bib0085) 2004; 18 Hallengard, Haller, Maltais, Gelius, Nihlmark, Wahren (bib0220) 2011; 18 Napolitano, Lo, Gotway, Mulligan, Barbour, Schmidt (bib0115) 2002; 16 Pires, Nelson, Pozniak, Fisher, Gazzard, Gotch (bib0190) 2005; 3 West, Jin, Rasheed, Penaloza-Macmaster, Ha, Tan (bib0245) 2013; 123 Grabmeier-Pfistershammer, Steinberger, Rieger, Leitner, Kohrgruber (bib0200) 2011; 56 Carcelain, Autran (bib0050) 2013; 254 Herasimtschuk, Hansen, Langkilde, Moyle, Andersen, Imami (bib0145) 2013; 173 Burton, Westrop, Eccles-James, Boasso, Nelson, Bower (bib0150) 2011; 166 Moyle, Daar, Gertner, Kotler, Melchior, O’Brien (bib0110) 2004; 35 Disis, Bernhard, Shiota, Hand, Gralow, Huseby (bib0095) 1996; 88 Sullivan, Hardy, Nelson, Gotch, Gazzard, Imami (bib0180) 2003; 17 Burton, Nelson, Hay, Gazzard, Gotch, Imami (bib0025) 2005; 142 Napolitano, Schmidt, Gotway, Ameli, Filbert, Ng (bib0120) 2008; 118 Lange, Valdez, Medvik, Asaad, Lederman (bib0230) 2002; 102 Brown, Angel (bib0090) 2005; 3 Gotch, Hardy, Imami (bib0250) 1999; 170 Abrams, Levy, Losso, Babiker, Collins, Cooper (bib0060) 2009; 361 Imami, Hardy, Nelson, Morris-Jones, Al-Shahi, Antonopoulos (bib0185) 1999; 118 Pires, Pido-Lopez, Moyle, Gazzard, Gotch, Imami (bib0135) 2004; 9 Montaner, Hogg, Wood, Kerr, Tyndall, Levy (bib0005) 2006; 368 Kassu, Marcus, D'Souza, Kelly-McKnight, Golden-Mason, Akkina (bib0195) 2010; 185 Robbins, Addo, Troung, Rathod, Habeeb, Davis (bib0235) 2003; 17 Levy, Durier, Krzysiek, Rabian, Capitant, Lascaux (bib0075) 2003; 17 Vasan, Hurley, Schlesinger, Hannaman, Gardiner, Dugin (bib0215) 2011; 6 Hansen, Kolte, Haugaard, Dirksen, Jensen, Ryder (bib0125) 2009; 23 El-Sadr (10.1016/j.vaccine.2014.09.072_bib0030) 2006; 355 Pires (10.1016/j.vaccine.2014.09.072_bib0010) 2004; 36 Vardas (10.1016/j.vaccine.2014.09.072_bib0055) 2012; 30 Abrams (10.1016/j.vaccine.2014.09.072_bib0060) 2009; 361 Brown (10.1016/j.vaccine.2014.09.072_bib0090) 2005; 3 Lange (10.1016/j.vaccine.2014.09.072_bib0230) 2002; 102 Molder (10.1016/j.vaccine.2014.09.072_bib0165) 2009; 28 Toubaji (10.1016/j.vaccine.2014.09.072_bib0105) 2007; 25 Cellerai (10.1016/j.vaccine.2014.09.072_bib0225) 2011; 6 Krohn (10.1016/j.vaccine.2014.09.072_bib0155) 2005; 7 Hocqueloux (10.1016/j.vaccine.2014.09.072_bib0035) 2010; 24 Pires (10.1016/j.vaccine.2014.09.072_bib0190) 2005; 3 Hansen (10.1016/j.vaccine.2014.09.072_bib0125) 2009; 23 Levy (10.1016/j.vaccine.2014.09.072_bib0075) 2003; 17 Herasimtschuk (10.1016/j.vaccine.2014.09.072_bib0140) 2008; 6 Napolitano (10.1016/j.vaccine.2014.09.072_bib0115) 2002; 16 Smith (10.1016/j.vaccine.2014.09.072_bib0130) 2010; 26 Hallengard (10.1016/j.vaccine.2014.09.072_bib0220) 2011; 18 Disis (10.1016/j.vaccine.2014.09.072_bib0095) 1996; 88 Gotch (10.1016/j.vaccine.2014.09.072_bib0250) 1999; 170 Hardy (10.1016/j.vaccine.2014.09.072_bib0085) 2004; 18 Imami (10.1016/j.vaccine.2014.09.072_bib0015) 2007; 1 Imami (10.1016/j.vaccine.2014.09.072_bib0045) 2013; 4 Imami (10.1016/j.vaccine.2014.09.072_bib0185) 1999; 118 Vasan (10.1016/j.vaccine.2014.09.072_bib0215) 2011; 6 Richman (10.1016/j.vaccine.2014.09.072_bib0020) 2009; 323 Adojaan (10.1016/j.vaccine.2014.09.072_bib0175) 2005; 39 Burton (10.1016/j.vaccine.2014.09.072_bib0150) 2011; 166 Burton (10.1016/j.vaccine.2014.09.072_bib0170) 2006; 308 Waller (10.1016/j.vaccine.2014.09.072_bib0100) 2007; 12 Montaner (10.1016/j.vaccine.2014.09.072_bib0005) 2006; 368 Carcelain (10.1016/j.vaccine.2014.09.072_bib0050) 2013; 254 Herasimtschuk (10.1016/j.vaccine.2014.09.072_bib0145) 2013; 173 Moyle (10.1016/j.vaccine.2014.09.072_bib0110) 2004; 35 Imami (10.1016/j.vaccine.2014.09.072_bib0040) 2001; 1 Valdez (10.1016/j.vaccine.2014.09.072_bib0080) 2003; 187 Grabmeier-Pfistershammer (10.1016/j.vaccine.2014.09.072_bib0200) 2011; 56 Napolitano (10.1016/j.vaccine.2014.09.072_bib0120) 2008; 118 Blazevic (10.1016/j.vaccine.2014.09.072_bib0160) 2006; 22 Kassu (10.1016/j.vaccine.2014.09.072_bib0195) 2010; 185 Sullivan (10.1016/j.vaccine.2014.09.072_bib0180) 2003; 17 Blattman (10.1016/j.vaccine.2014.09.072_bib0065) 2003; 9 Robbins (10.1016/j.vaccine.2014.09.072_bib0235) 2003; 17 West (10.1016/j.vaccine.2014.09.072_bib0245) 2013; 123 Hardy (10.1016/j.vaccine.2014.09.072_bib0205) 2007; 5 Pires (10.1016/j.vaccine.2014.09.072_bib0135) 2004; 9 Burton (10.1016/j.vaccine.2014.09.072_bib0025) 2005; 142 Gudmundsdotter (10.1016/j.vaccine.2014.09.072_bib0210) 2011; 29 Virgin (10.1016/j.vaccine.2014.09.072_bib0240) 2010; 464 Nacsa (10.1016/j.vaccine.2014.09.072_bib0070) 2005; 174 |
| References_xml | – volume: 5 start-page: 6 year: 2007 ident: bib0205 article-title: A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy publication-title: J Immune Based Ther Vaccines – volume: 18 start-page: 1577 year: 2011 end-page: 1581 ident: bib0220 article-title: Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation publication-title: Clin Vaccine Immunol – volume: 36 start-page: 783 year: 2004 end-page: 790 ident: bib0010 article-title: Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs publication-title: J Acquir Immune Defic Syndr – volume: 26 start-page: 425 year: 2010 end-page: 432 ident: bib0130 article-title: Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174 publication-title: AIDS Res Hum Retrovir – volume: 118 start-page: 1085 year: 2008 end-page: 1098 ident: bib0120 article-title: Growth hormone enhances thymic function in HIV-1-infected adults publication-title: J Clin Invest – volume: 174 start-page: 1913 year: 2005 end-page: 1921 ident: bib0070 article-title: Contrasting effects of low-dose IL-2 on vaccine-boosted simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cells in macaques chronically infected with SIVmac251 publication-title: J Immunol – volume: 1 start-page: 171 year: 2007 end-page: 179 ident: bib0015 article-title: Combined use of cytokines, hormones and therapeutic vaccines during effective antiretroviral therapy publication-title: Future HIV Ther – volume: 17 start-page: 343 year: 2003 end-page: 351 ident: bib0075 article-title: Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial publication-title: AIDS – volume: 170 start-page: 173 year: 1999 end-page: 182 ident: bib0250 article-title: Therapeutic vaccines in HIV.1 infection publication-title: Immunol Rev – volume: 4 start-page: 58 year: 2013 ident: bib0045 article-title: Long-term non-progression and broad HIV-1-specific proliferative T-cell responses publication-title: Front Immunol – volume: 39 start-page: 598 year: 2005 end-page: 605 ident: bib0175 article-title: Predominance of a rare type of HIV-1 in Estonia publication-title: J Acquir Immune Defic Syndr – volume: 102 start-page: 154 year: 2002 end-page: 161 ident: bib0230 article-title: CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection publication-title: Clin Immunol – volume: 173 start-page: 444 year: 2013 end-page: 453 ident: bib0145 article-title: Low-dose growth hormone for 40 weeks induces HIV-1-specific T-cell responses in patients on effective combination antiretroviral therapy publication-title: Clin Exp Immunol – volume: 185 start-page: 3007 year: 2010 end-page: 3018 ident: bib0195 article-title: Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection publication-title: J Immunol – volume: 7 start-page: 1405 year: 2005 end-page: 1413 ident: bib0155 article-title: A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies publication-title: Microbes Infect – volume: 28 start-page: 293 year: 2009 end-page: 298 ident: bib0165 article-title: Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multi-component fusion protein MultiHIV – study in domestic pigs publication-title: Vaccine – volume: 29 start-page: 5558 year: 2011 end-page: 5566 ident: bib0210 article-title: Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial publication-title: Vaccine – volume: 464 start-page: 224 year: 2010 end-page: 231 ident: bib0240 article-title: Immunology and the elusive AIDS vaccine publication-title: Nature – volume: 25 start-page: 5882 year: 2007 end-page: 5891 ident: bib0105 article-title: The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection publication-title: Vaccine – volume: 355 start-page: 2283 year: 2006 end-page: 2296 ident: bib0030 article-title: CD4+ count-guided interruption of antiretroviral treatment publication-title: N Engl J Med – volume: 3 start-page: 7 year: 2005 ident: bib0190 article-title: Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy publication-title: J Immune Based Ther Vaccines – volume: 23 start-page: 2123 year: 2009 end-page: 2131 ident: bib0125 article-title: Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study publication-title: AIDS – volume: 56 start-page: 118 year: 2011 end-page: 124 ident: bib0200 article-title: Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment publication-title: J Acquir Immune Defic Syndr – volume: 24 start-page: 1598 year: 2010 end-page: 1601 ident: bib0035 article-title: Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection publication-title: AIDS – volume: 9 start-page: 67 year: 2004 end-page: 75 ident: bib0135 article-title: Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy publication-title: Antivir Ther – volume: 9 start-page: 540 year: 2003 end-page: 547 ident: bib0065 article-title: Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo publication-title: Nat Med – volume: 6 start-page: e18164 year: 2011 ident: bib0225 article-title: Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors publication-title: PLoS ONE – volume: 3 start-page: 3 year: 2005 ident: bib0090 article-title: Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection publication-title: J Immune Based Ther Vaccines – volume: 187 start-page: 320 year: 2003 end-page: 325 ident: bib0080 article-title: Interleukin-2 increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s publication-title: J Infect Dis – volume: 323 start-page: 1304 year: 2009 end-page: 1307 ident: bib0020 article-title: The challenge of finding a cure for HIV infection publication-title: Science – volume: 30 start-page: 4046 year: 2012 end-page: 4054 ident: bib0055 article-title: Indicators of therapeutic effect in FIT-06, a phase II trial of a DNA vaccine, GTU((R))-multi-HIVB, in untreated HIV-1 infected subjects publication-title: Vaccine – volume: 361 start-page: 1548 year: 2009 end-page: 1559 ident: bib0060 article-title: Interleukin-2 therapy in patients with HIV infection publication-title: N Engl J Med – volume: 17 start-page: 1121 year: 2003 end-page: 1126 ident: bib0235 article-title: Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization publication-title: AIDS – volume: 1 start-page: 803 year: 2001 end-page: 816 ident: bib0040 article-title: Development of immunotherapeutic strategies for HIV-1 publication-title: Expert Opin Biol Ther – volume: 17 start-page: 628 year: 2003 end-page: 629 ident: bib0180 article-title: Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy publication-title: AIDS – volume: 16 start-page: 1103 year: 2002 end-page: 1111 ident: bib0115 article-title: Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone publication-title: AIDS – volume: 35 start-page: 367 year: 2004 end-page: 375 ident: bib0110 article-title: Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy publication-title: J Acquir Immune Defic Syndr – volume: 254 start-page: 355 year: 2013 end-page: 371 ident: bib0050 article-title: Immune interventions in HIV infection publication-title: Immunol Rev – volume: 18 start-page: 2199 year: 2004 end-page: 2202 ident: bib0085 article-title: Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses publication-title: AIDS – volume: 368 start-page: 531 year: 2006 end-page: 536 ident: bib0005 article-title: The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic publication-title: Lancet – volume: 6 start-page: 7 year: 2008 ident: bib0140 article-title: Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up publication-title: J Immune Based Ther Vaccines – volume: 142 start-page: 354 year: 2005 end-page: 361 ident: bib0025 article-title: Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection publication-title: Clin Exp Immunol – volume: 22 start-page: 667 year: 2006 end-page: 677 ident: bib0160 article-title: Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-multiHIV DNA vaccine publication-title: AIDS Res Hum Retrovir – volume: 118 start-page: 78 year: 1999 end-page: 86 ident: bib0185 article-title: Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy publication-title: Clin Exp Immunol – volume: 88 start-page: 202 year: 1996 end-page: 210 ident: bib0095 article-title: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines publication-title: Blood – volume: 308 start-page: 216 year: 2006 end-page: 230 ident: bib0170 article-title: Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: concomitant assessment of perforin, IFN-gamma and IL-4 secretion publication-title: J Immunol Methods – volume: 12 start-page: 22 year: 2007 end-page: 26 ident: bib0100 article-title: The role of sargramostim (rhGM-CSF) as immunotherapy publication-title: Oncologist – volume: 166 start-page: 191 year: 2011 end-page: 200 ident: bib0150 article-title: Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function publication-title: Clin Exp Immunol – volume: 6 start-page: e19252 year: 2011 ident: bib0215 article-title: In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers publication-title: PLoS ONE – volume: 123 start-page: 2604 year: 2013 end-page: 2615 ident: bib0245 article-title: PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells publication-title: J Clin Invest – volume: 6 start-page: e19252 year: 2011 ident: 10.1016/j.vaccine.2014.09.072_bib0215 article-title: In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers publication-title: PLoS ONE doi: 10.1371/journal.pone.0019252 – volume: 3 start-page: 7 year: 2005 ident: 10.1016/j.vaccine.2014.09.072_bib0190 article-title: Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy publication-title: J Immune Based Ther Vaccines doi: 10.1186/1476-8518-3-7 – volume: 26 start-page: 425 year: 2010 ident: 10.1016/j.vaccine.2014.09.072_bib0130 article-title: Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174 publication-title: AIDS Res Hum Retrovir doi: 10.1089/aid.2009.0052 – volume: 142 start-page: 354 year: 2005 ident: 10.1016/j.vaccine.2014.09.072_bib0025 article-title: Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2005.02918.x – volume: 355 start-page: 2283 year: 2006 ident: 10.1016/j.vaccine.2014.09.072_bib0030 article-title: CD4+ count-guided interruption of antiretroviral treatment publication-title: N Engl J Med doi: 10.1056/NEJMoa062360 – volume: 5 start-page: 6 year: 2007 ident: 10.1016/j.vaccine.2014.09.072_bib0205 article-title: A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy publication-title: J Immune Based Ther Vaccines doi: 10.1186/1476-8518-5-6 – volume: 36 start-page: 783 year: 2004 ident: 10.1016/j.vaccine.2014.09.072_bib0010 article-title: Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs publication-title: J Acquir Immune Defic Syndr doi: 10.1097/00126334-200407010-00004 – volume: 361 start-page: 1548 year: 2009 ident: 10.1016/j.vaccine.2014.09.072_bib0060 article-title: Interleukin-2 therapy in patients with HIV infection publication-title: N Engl J Med doi: 10.1056/NEJMoa0903175 – volume: 187 start-page: 320 year: 2003 ident: 10.1016/j.vaccine.2014.09.072_bib0080 article-title: Interleukin-2 increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s publication-title: J Infect Dis doi: 10.1086/346056 – volume: 18 start-page: 2199 year: 2004 ident: 10.1016/j.vaccine.2014.09.072_bib0085 article-title: Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses publication-title: AIDS doi: 10.1097/00002030-200411050-00014 – volume: 28 start-page: 293 year: 2009 ident: 10.1016/j.vaccine.2014.09.072_bib0165 article-title: Elicitation of broad CTL response against HIV-1 by the DNA vaccine encoding artificial multi-component fusion protein MultiHIV – study in domestic pigs publication-title: Vaccine doi: 10.1016/j.vaccine.2009.10.054 – volume: 7 start-page: 1405 year: 2005 ident: 10.1016/j.vaccine.2014.09.072_bib0155 article-title: A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies publication-title: Microbes Infect doi: 10.1016/j.micinf.2005.07.023 – volume: 368 start-page: 531 year: 2006 ident: 10.1016/j.vaccine.2014.09.072_bib0005 article-title: The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic publication-title: Lancet doi: 10.1016/S0140-6736(06)69162-9 – volume: 12 start-page: 22 issue: Suppl. 2 year: 2007 ident: 10.1016/j.vaccine.2014.09.072_bib0100 article-title: The role of sargramostim (rhGM-CSF) as immunotherapy publication-title: Oncologist doi: 10.1634/theoncologist.12-S2-22 – volume: 173 start-page: 444 year: 2013 ident: 10.1016/j.vaccine.2014.09.072_bib0145 article-title: Low-dose growth hormone for 40 weeks induces HIV-1-specific T-cell responses in patients on effective combination antiretroviral therapy publication-title: Clin Exp Immunol doi: 10.1111/cei.12141 – volume: 102 start-page: 154 year: 2002 ident: 10.1016/j.vaccine.2014.09.072_bib0230 article-title: CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection publication-title: Clin Immunol doi: 10.1006/clim.2001.5164 – volume: 25 start-page: 5882 year: 2007 ident: 10.1016/j.vaccine.2014.09.072_bib0105 article-title: The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection publication-title: Vaccine doi: 10.1016/j.vaccine.2007.05.040 – volume: 323 start-page: 1304 year: 2009 ident: 10.1016/j.vaccine.2014.09.072_bib0020 article-title: The challenge of finding a cure for HIV infection publication-title: Science doi: 10.1126/science.1165706 – volume: 185 start-page: 3007 year: 2010 ident: 10.1016/j.vaccine.2014.09.072_bib0195 article-title: Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection publication-title: J Immunol doi: 10.4049/jimmunol.1000156 – volume: 3 start-page: 3 year: 2005 ident: 10.1016/j.vaccine.2014.09.072_bib0090 article-title: Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection publication-title: J Immune Based Ther Vaccines doi: 10.1186/1476-8518-3-3 – volume: 23 start-page: 2123 year: 2009 ident: 10.1016/j.vaccine.2014.09.072_bib0125 article-title: Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study publication-title: AIDS doi: 10.1097/QAD.0b013e3283303307 – volume: 56 start-page: 118 year: 2011 ident: 10.1016/j.vaccine.2014.09.072_bib0200 article-title: Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181fbab9f – volume: 118 start-page: 78 year: 1999 ident: 10.1016/j.vaccine.2014.09.072_bib0185 article-title: Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.1999.01012.x – volume: 39 start-page: 598 year: 2005 ident: 10.1016/j.vaccine.2014.09.072_bib0175 article-title: Predominance of a rare type of HIV-1 in Estonia publication-title: J Acquir Immune Defic Syndr – volume: 17 start-page: 628 year: 2003 ident: 10.1016/j.vaccine.2014.09.072_bib0180 article-title: Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy publication-title: AIDS doi: 10.1097/00002030-200303070-00020 – volume: 254 start-page: 355 year: 2013 ident: 10.1016/j.vaccine.2014.09.072_bib0050 article-title: Immune interventions in HIV infection publication-title: Immunol Rev doi: 10.1111/imr.12083 – volume: 308 start-page: 216 year: 2006 ident: 10.1016/j.vaccine.2014.09.072_bib0170 article-title: Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: concomitant assessment of perforin, IFN-gamma and IL-4 secretion publication-title: J Immunol Methods doi: 10.1016/j.jim.2005.11.005 – volume: 16 start-page: 1103 year: 2002 ident: 10.1016/j.vaccine.2014.09.072_bib0115 article-title: Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone publication-title: AIDS doi: 10.1097/00002030-200205240-00003 – volume: 1 start-page: 171 year: 2007 ident: 10.1016/j.vaccine.2014.09.072_bib0015 article-title: Combined use of cytokines, hormones and therapeutic vaccines during effective antiretroviral therapy publication-title: Future HIV Ther doi: 10.2217/17469600.1.2.171 – volume: 17 start-page: 1121 year: 2003 ident: 10.1016/j.vaccine.2014.09.072_bib0235 article-title: Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization publication-title: AIDS doi: 10.1097/00002030-200305230-00002 – volume: 30 start-page: 4046 year: 2012 ident: 10.1016/j.vaccine.2014.09.072_bib0055 article-title: Indicators of therapeutic effect in FIT-06, a phase II trial of a DNA vaccine, GTU((R))-multi-HIVB, in untreated HIV-1 infected subjects publication-title: Vaccine doi: 10.1016/j.vaccine.2012.04.007 – volume: 88 start-page: 202 year: 1996 ident: 10.1016/j.vaccine.2014.09.072_bib0095 article-title: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines publication-title: Blood doi: 10.1182/blood.V88.1.202.202 – volume: 170 start-page: 173 year: 1999 ident: 10.1016/j.vaccine.2014.09.072_bib0250 article-title: Therapeutic vaccines in HIV.1 infection publication-title: Immunol Rev doi: 10.1111/j.1600-065X.1999.tb01337.x – volume: 6 start-page: 7 year: 2008 ident: 10.1016/j.vaccine.2014.09.072_bib0140 article-title: Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up publication-title: J Immune Based Ther Vaccines doi: 10.1186/1476-8518-6-7 – volume: 29 start-page: 5558 year: 2011 ident: 10.1016/j.vaccine.2014.09.072_bib0210 article-title: Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial publication-title: Vaccine doi: 10.1016/j.vaccine.2011.01.064 – volume: 6 start-page: e18164 year: 2011 ident: 10.1016/j.vaccine.2014.09.072_bib0225 article-title: Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors publication-title: PLoS ONE doi: 10.1371/journal.pone.0018164 – volume: 24 start-page: 1598 year: 2010 ident: 10.1016/j.vaccine.2014.09.072_bib0035 article-title: Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection publication-title: AIDS doi: 10.1097/QAD.0b013e32833b61ba – volume: 18 start-page: 1577 year: 2011 ident: 10.1016/j.vaccine.2014.09.072_bib0220 article-title: Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.05045-11 – volume: 35 start-page: 367 year: 2004 ident: 10.1016/j.vaccine.2014.09.072_bib0110 article-title: Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy publication-title: J Acquir Immune Defic Syndr doi: 10.1097/00126334-200404010-00006 – volume: 1 start-page: 803 year: 2001 ident: 10.1016/j.vaccine.2014.09.072_bib0040 article-title: Development of immunotherapeutic strategies for HIV-1 publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.1.5.803 – volume: 464 start-page: 224 year: 2010 ident: 10.1016/j.vaccine.2014.09.072_bib0240 article-title: Immunology and the elusive AIDS vaccine publication-title: Nature doi: 10.1038/nature08898 – volume: 174 start-page: 1913 year: 2005 ident: 10.1016/j.vaccine.2014.09.072_bib0070 article-title: Contrasting effects of low-dose IL-2 on vaccine-boosted simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cells in macaques chronically infected with SIVmac251 publication-title: J Immunol doi: 10.4049/jimmunol.174.4.1913 – volume: 17 start-page: 343 year: 2003 ident: 10.1016/j.vaccine.2014.09.072_bib0075 article-title: Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial publication-title: AIDS doi: 10.1097/00002030-200302140-00008 – volume: 123 start-page: 2604 year: 2013 ident: 10.1016/j.vaccine.2014.09.072_bib0245 article-title: PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells publication-title: J Clin Invest doi: 10.1172/JCI67008 – volume: 9 start-page: 540 year: 2003 ident: 10.1016/j.vaccine.2014.09.072_bib0065 article-title: Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo publication-title: Nat Med doi: 10.1038/nm866 – volume: 9 start-page: 67 year: 2004 ident: 10.1016/j.vaccine.2014.09.072_bib0135 article-title: Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy publication-title: Antivir Ther doi: 10.1177/135965350400900110 – volume: 22 start-page: 667 year: 2006 ident: 10.1016/j.vaccine.2014.09.072_bib0160 article-title: Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-multiHIV DNA vaccine publication-title: AIDS Res Hum Retrovir doi: 10.1089/aid.2006.22.667 – volume: 4 start-page: 58 year: 2013 ident: 10.1016/j.vaccine.2014.09.072_bib0045 article-title: Long-term non-progression and broad HIV-1-specific proliferative T-cell responses publication-title: Front Immunol doi: 10.3389/fimmu.2013.00058 – volume: 118 start-page: 1085 year: 2008 ident: 10.1016/j.vaccine.2014.09.072_bib0120 article-title: Growth hormone enhances thymic function in HIV-1-infected adults publication-title: J Clin Invest – volume: 166 start-page: 191 year: 2011 ident: 10.1016/j.vaccine.2014.09.072_bib0150 article-title: Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2011.04451.x |
| SSID | ssj0005319 |
| Score | 2.2228727 |
| Snippet | This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor... Abstract Background This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage... Background This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 7005 |
| SubjectTerms | Adult AIDS Vaccines - therapeutic use Allergy and Immunology Anti-Retroviral Agents - therapeutic use Antigens Antiretroviral agents Applied microbiology Biological and medical sciences CD4-positive T-lymphocytes CD4-Positive T-Lymphocytes - immunology Combined Modality Therapy - methods Cytokines - analysis Cytokines - therapeutic use Deoxyribonucleic acid DNA DNA vaccine Enzyme-Linked Immunospot Assay Flow Cytometry Fundamental and applied biological sciences. Psychology granulocyte-macrophage colony-stimulating factor Growth Hormone - therapeutic use Growth hormones HIV HIV Antigens - immunology HIV infections HIV Infections - immunology HIV Infections - therapy HIV-1 hormone replacement therapy Human immunodeficiency virus Human immunodeficiency virus 1 Human viral diseases Humans Immune-based therapy Immunization Immunophenotyping Immunotherapy Infections Infectious diseases interferon-gamma interleukin-2 interleukin-4 Lymphocyte Activation Lymphocytes Male Medical sciences Microbiology Middle Aged Miscellaneous Mortality Patients Peptides Perforin - analysis Plasma Proviruses - genetics recombinant vaccines somatotropin Tetanus Treatment Outcome Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, DNA - therapeutic use Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Virology |
| Title | Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X1401384X https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X1401384X https://www.ncbi.nlm.nih.gov/pubmed/25454870 https://www.proquest.com/docview/1625832299 https://www.proquest.com/docview/1635020616 https://www.proquest.com/docview/1652433624 https://www.proquest.com/docview/1846315698 |
| Volume | 32 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELfYJhASQlC-CqMyEtrT0iXxR-InBGVTQdpUQTflzUqcRHRMaVlapL7wX_H_cWcnDUise6nSxGc7yeX8O_t8P0Le-oZHeSxjj5cSHZQy92KVgTFUIjMi45xZOqDTMzk-558TkTQTbnUTVtnaRGuo87nBOfKjAIA6ap9S7xY_PGSNwtXVhkJjh-xh6jIM6YqSqAvxYJbYA9wM7vHAT7odPEeXw5-pwaVrjO5yqU6j8Kax6cEireGJlY7q4mYsasekk0fkYQMm6Xv39h-TO0XVI3cdveS6R-6dNgvnPXIwcSmq14d02u24qg_pAZ10yatBpneB8TF2ky5txZ-Q338J0ZndUuKigOjialVTs17Ov0NBmlY5_QYoeA7HbmfXGorjtEVR09FHTqcerhRQy1ABrV9bXhu4Bu935o0_XXgBnsOoXXsyh385KF_tGoUGTEvHRmcVtVHyRU6Ny_BLXQVtfFn1lJyfHE9HY68hfPCM4OHSy2JZlDL0Rc5KJpkBbSl9YbhJg0JELDAqTqNUsFxwoziT4NsXqswzlYaYcDliz8huBXf4gtASgGuBhGqgiTxWQWpKngFaMawAh1SqPuHtq9amyYaOpBxXug17u9SNhmjUEO0rDRrSJ8ON2MKlA7lNQLZ6pNu9rmCdNQxYtwlG_xMs6sbG1DrQdah9_dW3mNZPrKsc86RPBv_o66ajoQJ8zrDq_VaBdVfb5vvqkzeby2BrUC3SqpivsAwT4F7IQG4rI0LOABbxLWUA9LJASBX3yXP3AXWdBEgPTrT_cnsnX5H7-LBsYJHYJ7vL61XxGuDhMhuQneGvYGAtAfzGIzje-3B8NvnyBxsQaHg |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGJi4SQlBuhTGMBHtatiS-JH5ACHZRy9Zqgm7qm0kcR3RMaVlaUP8Ub_w_ju2kAYl1T3trYx_bbb4cnxOfcz6EXvuKRlnMY4_m3DgoeebFIgVlKFiqWEopsXRAvT7vnNCPQzZcQb_qXBgTVlnrRKuos7Ey78h3AjDUDfqEeDf57hnWKHO6WlNoOFgc6vlPcNnKt909uL9vwvBgf7Db8SpWAU8xGk69NOY656HPMpITThQsKfeZoioJNItIoEScRAkjGaNKUMLBgdQiz1KRhKaqb0Rg3BtozbSAIlj7sN8__tQElRBLJQKODfVo4A-bnKGds-0fiTKH5SaezBVXjcLLdsO7k6SEe5Q7co3LrV-7Cx7cR_cq8xW_d3h7gFZ00UI3HaHlvIVu9aqj-hbaPHZFsedbeNDkeJVbeBMfN-WyQaZ1aiJybFowrsUfot9_CeGRTWJxcUd4cj4rsZpPx9-gI06KDH8Fu3sMn10u2Ry6mxclusS7exQPPHM2gS0nBsx-YZl0oA0QNfI63VMvMNdMnLC9mMG3DOBeuklhAlUTwOFRgW1cvs6wcjWFsRugjmgrHqGTawHDY7RawC98inAOprI2FG6AfRqLIFE5TcE-UkSDC8xFG9H6VktV1V83NCDnsg60O5MVQqRBiPSFBIS00fZCbOIKkFwlwGscyTq7FvYDCVvkVYLR_wR1WWm1UgayDKUvP_vWivaH1jmP6bCNNv7B62KhoQCPgJih12sAy2a0xRPdRq8WzaDdDCySQo9npg9h4NDwgC_rw0JKwBCjS_qAmU0CxkXcRk_cA9QsEpwIcNv9Z8sX-RLd7gx6R_Ko2z98ju6YP86GNbF1tDq9mOkXYJxO041KI2D05bqV0B_OPqLC |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGEBMSQlC-CmMYCfa0rEn8kfgBIbRStYxNleimvHmJ44iOKS1LC-ofxgt_HWc7aUFi3dPe2sRnu83P57v47n4IvfEVjfKYxx4tuHFQityLRQbKULBMsYxSYumAjo55_4R-SliygX43uTAmrLLRiVZR5xNl3pF3AjDUDfqE6BR1WMSw23s__e4ZBilz0trQaTiIHOrFT3DfqneDLjzrt2HY-zg66Hs1w4CnGA1nXhZzXfDQZzkpCCcKplf4TFGVBppFJFAiTqOUkZxRJSjh4ExqUeSZSENT4Tci0O8tdDsiLDBrLEqiVXgJsaQi4OJQjwZ-ssoe6pzv_0iVOTY3kWWuzGoUXrUv3pumFTytwtFsXG0H2_2w9wDdrw1Z_MEh7yHa0GUL3XHUlosW2jqqD-1baHfoymMv9vBole1V7eFdPFwVzgaZ1qmJzbEJwrgRf4R-_SWExzadxUUg4enFvMJqMZt8g4Y4LXP8FSzwCXx2WWULaG5emegKH3QpHnnmlAJbdgwY_dJy6sA9wNbY6w9OvcBcMxHD9mIO33IAfuUGhQFUQwWHxyW2Efo6x8pVF8augya2rXyMTm4ECk_QZgm_8BnCBRjN2pC5wSqgsQhSVdAMLCVFNDjDXLQRbR61VHUldkMIciGbkLtzWSNEGoRIX0hASBvtL8WmrhTJdQK8wZFs8mxhZ5CwWV4nGP1PUFe1fqtkIKtQ-vKLb-1pP7FuekyTNtr5B6_LiYYCfANiut5uACxXvS3Xdhu9Xt4GPWdgkZZ6MjdtCAPXhgd8XRsWUgImGV3TBgxuEjAu4jZ66hbQapLgToAD7z9fP8lXaAtUj_w8OD58ge6a_83GN7FttDm7nOuXYKXOsh2rDjA6u2n98wdvRqWS |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+immunisation+plus+cytokine+and+hormone+therapy+improves+CD4+T-cell+counts%2C+restores+anti-HIV-1+responses+and+reduces+immune+activation+in+treated+chronic+HIV-1+infection&rft.jtitle=Vaccine&rft.au=Herasimtschuk%2C+Anna&rft.au=Downey%2C+Jocelyn&rft.au=Nelson%2C+Mark&rft.au=Moyle%2C+Graeme&rft.date=2014-12-05&rft.pub=Elsevier+Ltd&rft.issn=0264-410X&rft.volume=32&rft.issue=51&rft.spage=7005&rft.epage=7013&rft_id=info:doi/10.1016%2Fj.vaccine.2014.09.072&rft.externalDocID=S0264410X1401384X |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X14X00526%2Fcov150h.gif |